14th World Cancer & Anti- Cancer Therapy Convention November 21-22, 2016 Dubai, UAE

Biography:

Abstract:

Biography:

Rasha Aboelhassan is an Oncology Consultant at the Nasser Institute Hospital for Research and Treatment. She’s an expert in Medical Oncology, 3Dimention Radiation Therapy (3DCRT) and Intensity Modulated Radiation Therapy (IMRT), Cancer Research and Supportive Care. She’s an optimistic oncologist with experience over 20 years; and she’s the Principle Investigator of many international clinical trials working on new treatment for lung cancer, soft tissue sarcoma and lymphoma. She also has many online publications in the field of supportive care, breast cancer and rare cancers. She honoured a certificate of appreciation from Egyptian Ministry of Health and Cairo Medical Syndicate for her dedication towards her work.

Abstract:

Granulocytic sarcoma is a rare condition with a wide list of differential diagnosis, and debatable guidelines of treatment in different cancer centers; most of literature recommended systemic chemotherapy with or without radiation therapy and minor role surgery. Diagnostic methods like CT, MRI and PET CT can facilitate follow up of response to treatment more than diagnosis, which depend mainly on pathological picture, IHC and bone marrow examination. This is a report for a rare case of myeloid sarcoma who was presented by hard palatine fistula who was successfully treated with chemotherapy, surgery and radiation therapy.

Biography:

Abstract:

Biography:

Jamal Abdulkarim finished his Radiology Training in University Hospitals of Leicester, UK and obtained the FRCR. Currently, he is a Consultant Radiologist at George Eliot Hospital. He has interest in research particularly in the field of intravenous iodinated contrast media and MRI.

Abstract:

Metastatic bone disease is a common manifestation of advanced cancers particularly breast, prostate and lung. Currently many hospitals rely on traditional imaging technique such as bone scan, CT scan and more recently PET CT scan. However, all the above involve ionizing radiation and do not necessarily provide accurate information about the disease activity. Whole-body DW imaging (WB-DWI) is emerging as a promising bone marrow assessment tool for detection and therapy monitoring of bone metastases. Advantages of WB-DWI include the fact that no ionizing radiation is administered and no injection of isotopes or any contrast medium is necessary. Importantly, whole-body skeletal examinations are possible in reasonably short data acquisition times. WBDWI is commonly performed at 1.5T because of the ability to uniformly suppress fat over large fields of view. Recent technological advances including improved shimming routines and multi-transmit equipped MRI systems do allow WB-DWI data acquisitions at 3T. We present our local experience in whole body MRI using new Siemens Magnetum Skyra (2016) with advanced shimmering software reducing the above mentioned artefacts. 

Biography:

David Huang, upon completion of his PhD in Particle Physics, was trained at Medical Physics Residency Program at UC San Francisco, San Francisco. Then he worked at Memorial Sloan-Kettering Cancer Center, New York as a Faculty Physicist before moving to Long Island Jewish Medical Center, New York as Senior Medical Physicist. In 1995, he went back to Taiwan to help in establishing the first cancer center there for 7 years as Chairman of Medical Physics Department at Sun Yat-Sen Cancer Center in Taipei. In 2002, he went back to Memorial Sloan-Kettering Cancer Center as Associate Attending and Chief Physicist/Radiation Safety Officer at Rockville Centre Site. In 2014 summer, he retired from Memorial Sloan-Kettering Cancer Center and accepted offer from Duke University as Professor and Director at Medical Physics Graduate Program at Duke Kunshan University, China. Besides the clinical experiences, he is also a Professor at Young-Ming University, Taiwan and Central Taiwan Technology University, Taiwan, a Visiting Professor at Beijing University, School of Oncology, China and at Tsing-Hwa University, China and Adjunct Professor at University of Missouri, USA.

Abstract:

It is well accepted that local tumor control and normal tissue complications have sigmoidally shaped dose-response curves. The success of radiotherapy highly depends on the radiosensitivity of the particular tumor being treated relative to that of the surrounding normal tissues. For tumor sites where the tumor control curve is less steep than the normal tissue complication curve, the high doses required for tumor cure may cause unacceptable normal tissue complications. The goal of radiotherapy is to sufficiently separate the dose-response curves of local tumor control and normal tissues complication, and also the total volume of normal tissue irradiated. During the past three decades, advances in radiological imaging and computer technology have significantly enhanced our ability to achieve this goal through the development of three-dimensional image-based conformal therapy (3DCRT). Intensity-modulated radiation therapy (IMRT) is an especially advanced method of 3DCRT that utilizes sophisticated computer controlled radiation beam delivery to improve the conformality of the dose distribution to the shape of the tumor. This is achieved by varying beam intensities within each beam portal, as opposed to uniform beam intensities as in conventional 3DCRT. Both 3DCRT and IMRT utilize sophisticated strategies for patient immobilization and positioning, image-guided treatment planning, computer enhanced treatment verification, and image-guided treatment delivery (IGRT). In the heart of these techniques is advanced computer technology and 3D patient imaging with CT, MR and/or PET. Besides the advances in external beam treatment, there are also new developments in stereotactic body radiotherapy fields. Also, the proton and heavy charged particle treatment open another door for radiotherapy with promising results. All these advances in radiotherapy improve the outcome for the cancer treatment; increase tumor control rate while minimizing the side effect. Furthermore, combination of chemotherapy and radiotherapy and new fractionation scheme make the cancer treatment to another new era. In my talks, I will share with you few clinical examples to illustrate the powerful IMRT, IGRT, Proton therapy, and SBRT techniques applied in nowadays cancer managements. 

Biography:

Rasha Aboelhassan is an Oncology Consultant at the Nasser Institute Hospital for Research and Treatment. She’s an expert in Medical Oncology, 3Dimention Radiation Therapy (3DCRT) and Intensity Modulated Radiation Therapy (IMRT), Cancer Research and Supportive Care. She’s an optimistic oncologist with experience over 20 years; and she’s the Principle Investigator of many international clinical trials working on new treatment for lung cancer, soft tissue sarcoma and lymphoma. She also has many online publications in the field of supportive care, breast cancer and rare cancers. She honoured a certificate of appreciation from Egyptian Ministry of Health and Cairo Medical Syndicate for her dedication towards her work

Abstract:

Introduction: Pericardial mesothelioma is a rare condition with a reported prevalence <0.002%, with different clinical picture and clinical manifestations that include constrictive pericarditis, cardiac tamponade, and heart failure or pericardial tuberculosis. Here we present a rare case of pericardial mesothelioma of 30 years old female patient who presented by dyspnea and cardiac tamponade. MRI of the heart was showing pericardial mass where biopsy leaded the diagnosis of sarcomatiod mesothelioma of the heart.

Case Report: Female patient, 30 years old, presented, in May 2016, with chest pain and dyspnea. She was missed diagnosed as a case of congestive heart failure causing bilateral pleural effusion which had a mild improvement of symptoms with treatment of heart failure. Upon her follow up, her physician noticed pericardial thickness during echocardiography where CT and MRI was requested showing pericardial mass invading right atrium. Biopsy and pathological examination was showing poorly differentiated bland spindle cells with a collagenous stroma. Immunohistochemistry was done showing the following: 1- Pan cytokeratin positive on neoplastic cells; 2- Calritinin positive 10% of neoplastic cells; and 3- Vimentin and actin positive on neoplastic cells. This revealed the diagnosis of pericardial sarcomatiod mesothelioma invading right atrium. The patient had good supportive care including management of heart failure that was caused by filling defect of right atrium and impaired cardiac motility due to peri-cardiac mass, and chest tube fixation to drain bilateral pleural effusion. After improvement of general condition, the patient performance status was improved and she began chemotherapy in the form of ifosfamide and doxorubicin. Now she ended two cycles with good tolerance and clinical response.

Discussion: Pericardial mesothelioma accounts for approximately 6% of all mesotheliomas; approximately 120 cases have been reported. It has been reported at any age with male predominance of 3:1. Diagnosis of primary pericardial mesothelioma is usually late due to misdiagnosis with other conditions of pericardial diseases. Radiologically: Most cases presented with pericardial mass with or without effusion but still any specific radiological features that can differentiate pericardial mesothelioma from other pericardial neoplasms, but in some literatures it was described that chest radiography in patients with pericardial mesothelioma typically demonstrates cardiac enlargement, evidence of pericardial effusion, an irregular cardiac contour, or diffuse mediastinal enlargement and MR imaging also readily demonstrates cardiac encasement by a soft-tissue pericardial mass, as well as an associated pericardial effusion; but sometimes the presentation occurs with multiple pericardial masses. Treatment guidelines specific for pericardial mesothelioma is not yet established but, like other sarcomatiod mesothelioma, surgery for this case was not an option, so we began treatment of this case with ifosfamide and doxorubicin. 

Biography:

Abstract:

Background & Aim: Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with no effective treatment. PDAC cells are highly proliferative and metastatic. We have developed a new drug called Metavert that targets at the same time the glycogen synthase kinase 3 beta (GSK-3β) and histone deacetylase (HDAC), important mediators of cancer progression. The aim of this study was to test this agent for treatment of PDAC.

Methods: PDAC cell lines, patient-derived circulating tumor cells (CTCs), and normal cells were treated with different doses of Metavert and cell survival, apoptosis, epithelial to mesenchymal transition (EMT) markers, and invasion ability were measured. Treatments were performed alone and in combination with gemcitabine or exposure to irradiation. In vivo, Kras^LSL-G12D/+; Trp53^LSL-R172H/+; and Pdx^cre (KPC) mice were intra-peritoneally injected with Metavert (5mg/Kg) 3 times per week from age 2 months until death. Survival and number of metastasis were determined. Pancreatic lesions and tumor grades as well as fibrosis and inflammation were measured by immunohistochemistry. Cytokine production and expression of cytokine receptors were measured in tumor cells and in cells present in the tumor microenvironment.

Results: Metavert significantly (at nano-molar concentrations) decreased cancer cell survival and increased apoptosis in several PDAC cells lines. The anti-cancer effect was stronger than the effect of the combination of HDAC and GSK-3β inhibitors. The same doses of Metavert did not affect survival of normal hepatocytes and pancreatic ductal cells. Metavert decreased the survival of CTCs. Metavert increased histone acetylation, inhibited GSK-3β activity, decreased expression of markers of EMT/ metastasis and cancer stemness, and prevented migration of the cancer cell lines and CTCs. Furthermore, Metavert sensitized PDAC cells and CTCs to gemcitabine and radiotherapy as well. Treatment with Metavert significantly increased KPC mice survival by ~50%. Histologic examination showed that Metavert treatment inhibited formation of both early pancreatic intraepithelial neoplasia (PanIN) lesions and late lesions (carcinoma) in the pancreas of these animals. Distal metastasis was decreased from 29% in control KPC mice to 0% in Metavert treated KPC mice. Fibrosis and M2 macrophages levels were decreased in Metavert treated mice.

Conclusion: We have designed and synthesized a novel drug that shows a significant anti-cancer effect in vitro in PDAC cells and CTCs and in the most aggressive mouse model of experimental PDAC. Importantly, Metavert increased the survival of KPC mice and prevented metastasis in vivo with no significant toxicity to normal cells. Pre-clinical toxicity studies are ongoing and the drug is expected to be approved for clinical testing within one year.

Biography:

Gabriela El Haje Lobo has completed her Medical degree from UNIPLAC University in Brasilia, 2011. Currently, she is in her 3^rd of residency in Nuclear Medicine at a private service in Brasilia, Brazil

Abstract:

Introduction: Neuroendocrine tumors (NET) generally express somatostatin receptors (SR), allowing its treatment by radiolabeled somatostatin analogues (SA). Other tumors expressing these receptors are also amenable to such therapy.

Purpose: This paper aims to present the experience and the treatment results of 42 patients with ¹⁷⁷Lu-octreotate in the Federal Capital of Brazil.

Subjects & Methods: 42 patients with progressing neuroendocrine and no neuroendocrine tumors with SR expression started the Rotterdam protocol with ¹⁷⁷Lu-octreotate, from January 2008 to June 2016. These patients were selected after staging by anatomic imaging methods and SA affinity confirmed by scintigraphy, observing proper inclusion and exclusion criteria. Adverse effects during and after the doses administration were analyzed. 33 patients completed at least one cycle of treatment (4 doses of 200 mCi) and were assessed for clinical, laboratorial and anatomic response (complete, partial, stable or progression).

Conclusion: This ongoing experience of therapy with ¹⁷⁷Lu-octreotate reproduced the literature data for safety and also for low incidence of side effects. Not only patients with NET, but also those with other tumors expressing affinity for the somatostatin analogs were benefited from this therapy.

Biography:

Amani Mahbub  has completed MSc in Biomedical Basis of Disease in 2010 and PhD in Anti-Cancer Potential of Polyphenols in Treatment of Leukemia in 2015 at the Sheffield Hallam University of Biomedical Research Centre – Cancer Research, Sheffield, UK. She has been interested in investigating the biological effects of a number of nutraceutical compounds such as polyphenols alone and in combination with chemotherapies on the induction of apoptosis, reduced cell proliferation and signalling pathways that involved in the pathogenesis of leukaemias. She also has four published papers in the Journal of Pathology (2012), the Journal of Anti-cancer Agents in Medicinal Chemistry (2013) and recently two in Nature (2015), and two more papers under publications. In addition, she was awarded, the Alastair Currie prize for the best poster presentation at the Pathological Society of Great Britain & Ireland Conference in 2012, Sheffield, UK; and Best Poster Prize at 4^th International Conference on Blood Malignancies & Treatment, 2016 in Dubai, UAE. Currently, she is working at Umm Al-Qura University in Laboratory Medicine of Applied Medical Sciences College – Pathology Department, Makkah, KSA.

Abstract:

Background: The study aimed to assess the effects of polyphenol when used in combination with doxorubicin and etoposide, and determine whether polyphenols sensitized leukemia cells, causing cell-cycle arrest, inhibition of cell proliferation and induction of apoptosis. The rationale being that in some solid tumors, polyphenols have been shown to sensitize cells to apoptosis and/or cell-cycle arrest, potentially reducing doses, whilst maintaining efficacy.

Method: Quercetin, apigenin, emodin, rhein, cis-stilbene were investigated alone and in combination with etoposide and doxorubicin in two lymphoid (Jurkat and CCRF-CEM) and two myeloid (THP-1 and KG-1a) leukemia cells lines. Measurements were made of ATP levels (CellTiter-Glo®assay), cell-cycle progression (propidium iodide (PI) staining and flow cytometry) and apoptosis (NucView-caspase-3 assay and Hoechst 33342/PI staining). The effects of these combinations on the apoptotic pathway (caspases-3, -8 and -9 Glo®luminescent assays), glutathione levels (GSH-Glo™-glutathione assay and cell tracker™ green-5-chloromethylfluorescein-diacetate-glutathione staining) and DNA damage (Alexa Fluor® 647 Mouse anti-H2AX staining) were also determined.

Results: Doxorubicin and etoposide in combination with polyphenols synergistically reduced ATP levels, induced apoptosis and increased S- and/or G₂/M-phase cell-cycle arrest in lymphoid leukemia cell lines. In the myeloid cell lines, doxorubicin and etoposide displayed differential effects. Doxorubicin had a synergistic or additive effect when combined with quercetin, apigenin, emodin and cis-stilbene, but had an antagonistic effect when combined with rhein. Combination treatment caused a synergistic down regulation of glutathione (GSH) levels and increased DNA damage, driving apoptosis via caspase 8 and 9 activation. However, in myeloid cells were an antagonist effect this was associated with an up-regulation of GSH levels, a reduction in DNA damage and apoptosis.

Conclusion: Doxorubicin and etoposide activity can be enhanced by polyphenols, particularly in lymphoid leukemia cells, although effects were strongly dependent on type of cell line, with some interactions were antagonistic in myeloid cell lines.

Biography:

Khadijeh Jamialahmadi has completed her PhD from Tehran University of Medical Sciences, School of Pharmacy, Tehran, Iran. She is an Assistant Professor in the Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran. She has published more than 30 papers in reputed journals. Her current research interests are cancer targeted therapy, cancer epigenetics, identification of new biomarkers and therapeutic targets in cancer and multi drug resistance in cancer.

Abstract:

Breast cancer is the most frequent malignancy in women worldwide. Oestrogen receptor α (ERα) antagonists like tamoxifen are used in endocrine therapies for ERα-positive (ERα+) breast cancer patients. Unfortunately, the clinical benefit is limited due to intrinsic and acquired drug resistance. Gankyrin (P28GANK) is a newly defined oncoprotein which was reported to confer a multidrug resistant phenotype in some cancer cells. Gankyrin also functions as a dual-negative regulator of the two most important tumor suppressor pathways: (I) INK4-CDK-pRb, and (II) ARF-MDM2-p53. In the present study, the levels of protein expression and mRNA transcripts were determined using immunohistochemical analysis and Real-Time quantitative PCR in 72 matched formalin-fixed paraffin-embedded and fresh frozen breast cancer tissues (36 tamoxifen resistant and 36 tamoxifen sensitive). Overexpression of P28GANK was present in about 56% of the tamoxifen sensitive breast cancer patients and more frequently (91%) in tamoxifen-refractory tumors. P28GANK gene was also found to be overexpressed at the protein level in tamoxifen resistance patients compared to tamoxifen sensitive samples (p=0.045). These results for the first time suggest that Gankyrin plays a role in tamoxifen-resistant breast cancer, and the inhibition of this oncoprotein may be a potential target for re-sensitizing the resistant breast cancer patients to tamoxifen-treatment in endocrine-resistant breast cancer patients.

Biography:

Mahdiss Mohamadianamiri completed her graduation in Gynecology in the year 2009. She completed her Fellowship of Oncology in 2016 from Shahid Beheshti Medical University. Currently, she is serving as Assistant Professor in Iran Medical University.

Abstract:

Introduction: Among gynecologic cancers, epithelial ovarian cancer (EOC) is the major cause of mortalities in the United States, accounting for 3.6% of all types of gynecologic cancers. The major reason for this poor treatment is that most EOC patients are frequently involved in an advanced stage of the disease.

Case Presentation: Hereby, we report a 70-year-old female with ovarian cancer in which an isolated metastatic axillary lymph node was detected following cyto-reductive surgery and adjuvant chemotherapy.

Results: She had a sonography demonstrating hypoechoic solid mass in pelvis attached to fundus (adnexal mass). Serum CA-125 level was 102 μm/ml. The patient had history of laparotomy and TAH+BSO (please write in detail) with the pathology of poorly differentiated adenocarcinoma of pelvic mass and both ovaries. A 3*3 mass lesion was palpable in right axilla and abdominal CT scan was normal. The thorax CT revealed lobulated mass lesion in right axillary area due to lymphadenopathy.Histopathological and IHC examination of the axillary lymph node revealed Metastasic papillary serous axillary lymph node originated from ovary   and it was confirmed in second option. She has received Taxel+carboplatinum chemotherapy and the axillary lymph nodes revealed shrinkage in size

Conclusion: In current case, we represent the importance of differentiating accurately ovarian metastasis to the axillary area from primary breast cancer because prognosis and treatment differ significantly.

Biography:

Abstract:

Biography:

Racha Sabbagh Dit Hawasli is a Clinical Pharmacy Graduate from the Lebanese American University. She has worked in community and hospital pharmacy settings before going into research. She is currently a PhD Researcher at Kingston University London, working on the diffusion of innovation in health, more specifically, the feasibility of ambulatory chemotherapy in Lebanon. She expanded her research topic to include occupational exposure to cytotoxic drugs in academic and healthcare settings. Her expertise lies in quantitative and qualitative methodologies and pharmacoeconomic modeling as she has conducted several assessments in this context over the past 4 years. She has also established strong connections with experts from the UK in occupational exposure, and is currently working on setting guidelines for the safe handling of cytotoxic drugs in academic research laboratories. She has several publications in international journals, and presented part of her work as posters at two annual meetings for the British Oncology Pharmacy Association (BOPA). She is a member of the International Society of Oncology Pharmacy Practitioners (ISOPP).

Abstract:

It has been often reported that cancer patients experience a sense of loss of control towards their fluctuating symptoms, disease management impacting their autonomy, and their life as a whole. Studies have shown that shared decision making can empower patients, improve adherence and overall quality of life. Therefore, governments have initiated policies supporting the involvement of patients in the management of their own care. One innovation in this context is ambulatory chemotherapy (AC), delivering chemotherapy to patients outside the hospital using a portable elastomeric infusion pump. AC is renowned for decreasing cost of care, enhancing quality of life, and empowering patients to regain control and normalcy. AC has become the standard of care for certain cancers in most developed countries. In Lebanon, a developing Mediterranean country with substantial demands for healthcare services and outstanding expenses, AC is not widely adopted yet. This research work entails the development of a framework to facilitate the uptake of AC in Lebanon. It involved a needs assessment of stakeholders and patients to understand the barriers and facilitators. This talk will present an overview of ambulatory chemotherapy, the types of ambulatory pumps used the patient journey, and finally a briefing of the work done in Lebanon to assess the feasibility of implementing this treatment modality. It is essential to assess the needs of the patients and the healthcare system for ambulatory chemotherapy to facilitate the commissioning this treatment modality and foster a strong infrastructure to support it.

Biography:

Abstract:

Biography:

Mu Ju Wei completed his MD at Cancer Hospital of CAMS and PUMC. He is the Deputy Director and Professor of Department of Thoracic Surgery. He majored in minimally invasive thoracic surgery including surgical treatment of malignant lung, esophageal and mediastinal lesions. He has completed and participated in several national natural funds, province natural funds, and published several papers in oncogene and BMJ open, et al. He is also serving as Editorial Board Member of several magazines (including JTD and WJG).

Abstract:

Data of consecutive 1553 patients who underwent video assisted thoracoscopic surgical (VATS) pulmonary resection for lung cancer in the Department of Thoracic Surgery of Cancer Hospital of CAMS and PUMC between November 2014 and January 2016 were prospectively collected and analyzed. There were 716 males and 837 females. The mean age was 58.90 years (25 to 82 years) and the conversion rate was 2.7% (42/1553) in this cohort. After propensity score matching, there were 207 patients in single-port and two-port group, and 680 patients in three-port group. Propensity-matched analysis demonstrated that there were no significant differences in duration of operation (129 versus 131 minutes, P=0.689), intra-operative blood loss (63 versus 70 mL, P=0.175), number of dissected lymph nodes (12 versus 13, P=0.074), total hospital expense ($9928 versus $9956, P=0.884) and cost of operation ($536 versus $535, P=0.879) between VATS single-port, two-port and conventional three-port pulmonary resection groups. There was no significant difference in the complication rate between two groups (5.3% versus 4.7%, P=0.220). However, compared with three-port group, patients who underwent single port and two-port experienced shorter postoperative length of stay (6.24 versus 5.61 d, P=0.033), shorter duration of chest tube (4,92 versus 4,25 d, P=0.008), and decreased volume of drainage (926 versus 791 d, P=0.003). We concluded that the short term outcomes between VATS single-port, two-port and conventional three-port groups for the surgical treatment of lung cancer were comparable. However, compared with three-port VATS pulmonary resection, single-port and two-port were associated with shorter postoperative length of stay, shorter duration of chest tube, and decreased volume of drainage.

Biography:

Abstract:

Background: The objective of the paper is to create awareness among people about alternative and complimentary methods to protect themselves from Chronic Airway diseases including throat and lung cancers. The following changes take place in airways as a result of diseases: 1) Inflammation: It is a physiological process and plays the role of immunological defense against infection, injury or allergy. 2) Hyper secretion of mucus: It is one of the important clinical and pathological features of airway inflammatory diseases including throat and lung cancers. It is the result of goblet cell hyperplasia in respiratory mucosa and is a prominent feature of inflammation. Chronic mucus hyper secretion is a potential risk factor for an accelerated loss of lung function. The thick viscous mucus in the lungs will be conducive to pathogens. Continued inflammation and mucus hyper secretion may significantly contribute to transformation of normal cells into cancer cells. 3) Broncospasm: is an additional factor in asthma patients. The three factors together cause breathlessness. Further, chronic inflammation and its prominent feature, hyper secretion of mucus are the fuses that ignite cancer. Without these factors, there cannot be inflammatory cell recruitment to the site of infection, injury or allergy. Continued presence of inflammatory cells or carcinogens may lead to cycles of tissue injury and repair resulting in carcinogenesis of airways. Therefore, treating these two factors is very important for airway integrity and to protect from airway diseases including throat and lung cancers. For resolution of the said factors, a rapid programmed clearance of excess mucus is necessary. As a result, the origin of it inflammation gets resolved. A little medicinal assistance may become necessary.

Methods: Exercises are important expectorant therapies. They are mucokineses and a recipe for healthy ageing. Exercises strengthen the remodeled airways and reset the biological ageing process. They are a) Upper airway passages cleansing Exercises: They help in cleansing mouth, nose and pharynx, the primary sites of colonization of pathogens and the sinuses, the way stations to the brain. These exercises should be practiced with hypertonic solution i.e., a solution having greater osmotic pressure than that of cells or body fluids and draws water out of cells thus inducing plasmolysis. b) Bronchial airways cleaning exercises: c) Physical, aerobic and yogic exercises help in strengthening the inspiratory and expiratory muscles.

Conclusions: Any mucus related respiratory health problem commences from upper airway passages and spreads to tracheo bronchial tree as they constitute only one path way. The mucociliary clearance mechanism becomes defunct when excess and sticky mucus forms. Once the upper airway passages are cleaned of it, the defunct cilia become active and ciliate mucus towards nasal passages and it can be blown out easily. The respiratory and other diseases originating from its pathway come under control. The exercises are based on the concept “Once the offending factor, excess mucus is removed, the origin of it, inflammation gets resolved”. There will be no scope for formation of lesions leading to carcinomas in the lungs and if already lesions are formed, treating them will become easy. 

Biography:

M A Nezami is a Board Certified Physician graduated from USC and UCSF residencies and fellowship and trained in Integrative Cancer Therapy. He serves as Researcher and national and international Speaker, in Oncology and Epigenetic field. He has been involved in many research projects and publications/presentations. He is an Inventor and Innovator and has designed a new method of treating advanced cancer, called Multi Molecular Targeted Epigenetic Therapy (MTET). With this method, over the last 7 years, he has successfully treated many patients, mostly with advanced cancer who had failed conventional methods.

Abstract:

There are several barriers that influence the effective treatment of solid tumors by conventional therapies. These barriers include tumor heterogeneity and the genetic instability of cancer. It has been hypothesized that these problems may be managed by targeting angiogenesis, as angiogenic signals modify the micro-environmental cross-talk by the tumor. Oncogenic driver events may also influence the viability and clinical behavior of a given tumor. Some driver mutations are found to be targets for therapy, whereas others play crucial roles in resistance to therapy. The challenge is that tumor cells have a very sophisticated mechanism of survival, by switching their driving pathways and signaling transduction pathways in a dynamic fashion. This understanding has prompted efforts aimed at treating tumor cells with multiple drugs to inhibit as many targets as possible. The majority of these combination therapies have failed to be clinically advantageous. Research of epigenetic regulations of these targets, including angiogenesis, is relevant and exciting. We present a summary of cases of advanced Stage IV patients with heterogeneous cancer who were treated using a novel epigenetic therapy, in a protocol called multi targeted epigenetic therapy (MTET), resulting in independent “antiangiogenic response”, as well as decreased heterogeneity of tumors, and overall reduction of tumor burden. These reductions were measured by serum/plasma VEGF measurements as a biomarker for vasculogenesis, circulatory tumor DNA and by circulatory tumor cells analysis. These markers translated to improved progression free or overall survival, and proved to be prognostic in many cases. We conclude that this small sample presents considerable effect size, and may impact the current practice of oncology by providing better prognostic and therapeutic tools targeting epigenetic aberrancies in refractory heterogeneous disease, by regulating the epigenome.